NCT03923114Completed
Imaging Pituitary ActiVation by Exendin
iPAVE - Imaging Pituitary ActiVation by Exendin
Source: ClinicalTrials.gov · Last updated 22 May 2024
Brief summary (registry, in English)
The main goal is the comparison of pituitary uptake of Ga-68-NODAGA-exendin-4 in patients with and without adequate response (based on HbA1c or weight loss) to GLP-1R agonist treatment.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 11 Apr 2019
- Start date
- 23 May 2019
- Primary completion date
- 3 Apr 2024
- Lead sponsor
- Radboud University Medical Center
- Diseases
- Type 2 diabetes
- NCT number
- NCT03923114
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 23 May 2019 to the primary completion date, 3 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Exclusion criteria for MR:
- Fragments, clips or devices in brain, eyes, spinal canal
- Implantable defibrillator or pacemaker (wires)
- Mandibular magnetic implants
- Neurostimulator, bladder stimulator, non-removable insulin pump
- Metal tissue-expander in chest
- Cochlear implant
- Ossicular replacement prosthesis
Other illness
- Liver disease
- Renal disease
- Pituitary disorder
Age
- Age \<18 years
Other
- Pregnancy or the wish to become pregnant within 6 months after the study
- Breastfeeding
- Inability to sign informed consent
Who the study is looking for
- Patients with treatment response:
- Age ≥18 years
- Subject is diagnosed with type 2 diabetes
- Subject showed response to GLP-1RA treatment
- Ability to sign informed consent
- Patients without treatment response:
- Age ≥18 years
- Subject is diagnosed with type 2 diabetes
- Subject showed no response to GLP-1RA treatment
- Ability to sign informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Radboud University Medical Center Coordinator of this site? Confirm its status | Nijmegen | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.